Megan O Nakashima, MD, FCAP, CAP Hematopathology Committee Chair, discusses Brentuximab Vedotin for DLBCL. “ECHELON-3 is a randomized, double-blind, placebo-controlled trial, generally considered to be the most meaningful type of study,” said Dr. Nakashima.
For the full article click here: FDA Approves Brentuximab Vedotin for DLBCL